The NanoBiotechnology Group is mainly focused on the use of bioactive molecules and nanoparticles in nanomedicine & nanotechnology. It possesses a multidisciplinary philosophy, combining the expertise of Dr. Alvaro Somoza, an expert in the use of modified oligonucleotides and nanostructures in nanomedicine, and Dr. Begoña Sot, an expert in protein engineering and therapeutic proteins. The group deals with several research lines, centered on the use of modified oligonucleotides and proteins to create new nanomedical tools and sensors.

Dr. Alvaro Somoza´s group:

– Nanoparticles in Drug Delivery, using different nanostructures to deliver different drugs and nucleic acids for the treatment of different diseases.

– The design of new strategies for efficient editing of Uveal Melanoma and Pancreatic cancer cell lines based on the delivery ofthe CRISPR system.

– Nanosensors for multiples diseases, such as Uveal, Melanoma, Pancreatic cancer or Duchenne Muscular Dystrophy.

– Modified magnetic nanoparticles for the treatment of pancreatic cancer. (NoCanTher project)

Dr. Begoña Sot´s group:

– The design of new strategies for efficient editing of Uveal Melanoma and Pancreatic cancer cell lines based on CRISPR proteins delivery.

– Design of new immunotherapy tools based in engineered molecular chaperones and gold nanoparticles able to load Antigen Presenting Cells with antigens and siRNAs for their use in immunotherapy.

– Effect of molecular chaperones in amyloid fibers assembly.

– Antibacterial activity of metal nanoparticles conjugated with modified bactericidal peptides.

Funded Projects

Active Projects

Nanoestructuras inteligentes contra el melanoma de úvea y el cáncer de páncreas (SAF2017-87305-R)
Funding agency: Ministerio de Economía, Industria y competitividad
Preparación y Escalado de Nanopartículas Modificadas Bajo Estándares Farmacéuticos (IND2017/IND-7809)
Funding agency: Comunidad de Madrid
Nuevas aproximaciones para el tratamiento y detección de melanoma de úvea basadas en nanopartículas de oro funcionalizadas
Funding agency: Asociación Española Contra el CáncerNanomedicine Upscaling for Early
Clinical Phases of Multimodal Cancer Therapy (NoCanTher)
Funding agency: European Commission , H2020, REF: GA 685795
WEB: NoCanTher 
MicroRNA based nanotherapies for the detection and treatment of muscular diseases (NanomiR)

Funding agency: EuronanoMed II (MINECO). REF: PCIN-2016-167
WEB: NanoMir

Past Projects
Diseño y evaluación de agentes terapéuticos y sensores basados en ARNs no codificantes y nanoestructuras (miRGold)
Funding agency: MINECO, REF: SAF2014-56763-R
Oligonucleotidos modificados en nanomedicina: deteccion de secuencias de acidos nucleicos e inhibicion de la expresion genica mediante arn interferente
Funding agency: MINECO, REF: SAF2010-15440
Multifunctional Nanotechnology for selective detection and Treatment of cancer (MULTIFUN)
Funding agency: European Commission , FP7, REF: 262943
WEB: Multifun

Previous project:

The aim of the collaborative project MULTIFUN is to develop functionalized nanoparticles for the detection and treatment of breast and pancreatic cancer.

Seventh Framework Programme grant agreement no. 262943